Lumipulse测定的脑脊液生物标志物用于阿尔茨海默病早期检测
这项回顾性尸检对照研究纳入49例腰椎穿刺时认知正常的脑捐献者,使用Lumipulse测定脑脊液Aβ42和p-tau181。p-tau181/Aβ42比值对阿尔茨海默病神经病理改变的鉴别准确度最佳(AUC=0.97)。
要点
- 脑脊液p-tau181/Aβ42比值对AD神经病理改变有极好鉴别准确度(AUC=0.97)。
- p-tau181/Aβ42与CERAD神经炎性斑块评分和Braak NFT分期强相关。
- 研究提供II级证据支持Lumipulse测定的脑脊液标志物用于AD早期检测。
核心结论
- 本研究支持Lumipulse测定的脑脊液Aβ42和p-tau181,尤其是p-tau181与Aβ42的比值,用于阿尔茨海默病病理生理过程的早期检测。
- 本研究提供II级证据表明脑脊液p-tau181/Aβ42的Lumipulse测定能准确区分有和无阿尔茨海默病神经病理改变的认知正常参与者。
研究设计与样本
- 回顾性研究,纳入美国国家阿尔茨海默病协调中心脑捐献者中腰椎穿刺时认知正常且接受Lumipulse法测定脑脊液Aβ42和p-tau181者,所有捐献者来自华盛顿大学Knight ADRC。
- 根据美国国家衰老研究所-阿尔茨海默病协会标准对AD神经病理改变(ADNC)进行分期,参与者分为AD-(无AD/低ADNC)和AD+(中间型/高ADNC)两组。
- 采用控制年龄、性别、APOE ε4和腰椎穿刺至死亡间隔的二元逻辑回归预测概率生成AUC统计量,评估各标志物区分AD状态的准确度。
- 共49例脑捐献者,腰椎穿刺时平均年龄79.3岁(SD=5.6),死亡时平均年龄87.1岁(SD=6.5)。
- 49例中24例(49%)为男性,47例(95.9%)为白人,20例(40.8%)经尸检确认AD,腰椎穿刺至死亡平均间隔7.76年(SD=4.31)。
主要发现
- 脑脊液p-tau181/Aβ42是AD的最佳预测指标,具有极好的鉴别准确度(AUC=0.97,95%CI 0.94-1.00,p=0.003)。
- 脑脊液p-tau181单独的鉴别准确度次之(AUC=0.92,95%CI 0.84-1.00,p=0.001),其次是脑脊液Aβ42单独(AUC=0.92,95%CI 0.85-1.00,p=0.007),脑脊液t-tau的鉴别准确度数值最低(AUC=0.87,95%CI 0.76-0.97,p=0.005)。
- 控制常见共病神经病理后效应仍存在。
- 脑脊液p-tau181/Aβ42与CERAD神经炎性斑块评分和NFT的Braak分期强相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: CSF biomarkers of Aβ42 and phosphorylated tau (p-tau181) are used clinically for the detection of Alzheimer disease (AD) pathology during life. CSF biomarker validation studies have largely used clinical diagnoses and/or amyloid PET imaging as the reference standard. The few existing CSF-to-autopsy studies have been restricted to late-stage AD. This CSF-to-autopsy study investigated associations between CSF biomarkers of AD and AD neuropathologic changes among brain donors who had normal cognition at the time of lumbar puncture (LP). METHODS: This was a retrospective study of brain donors from the National Alzheimer's Coordinating Center who had normal cognition at the time of LP and who had measurements of CSF Aβ42 and p-tau181 performed with Lumipulse assays. All brain donors were from Washington University Knight ADRC. Staging of AD neuropathologic change (ADNC) was made based on National Institute on Aging-Alzheimer's Association criteria. For this study, participants were divided into 2 categories: "AD-" (no AD/low ADNC) and "AD+" (intermediate/high ADNC). Accuracy of each biomarker for discriminating AD status was evaluated using area under the curve (AUC) statistics generated using predicted probabilities from binary logistic regressions that controlled for age, sex, APOE ε4, and interval between LP and death. RESULTS: The average age at LP was 79.3 years (SD = 5.6), and the average age at death was 87.1 years (SD = 6.5). Of the 49 brain donors, 24 (49%) were male and 47 (95.9%) were White. 20 (40.8%) had autopsy-confirmed AD. The average interval from LP until death was 7.76 years (SD = 4.31). CSF p-tau181/Aβ42 was the optimal predictor of AD, having excellent discrimination accuracy (AUC = 0.97, 95% CI 0.94-1.00, p = 0.003). CSF p-tau181 alone had the second-best discrimination accuracy (AUC = 0.92, 95% CI 0.84-1.00, p = 0.001), followed by CSF Aβ42 alone (AUC = 0.92, 95% CI 0.85-1.00, p = 0.007), while CSF t-tau had the numerically lowest discrimination accuracy (AUC = 0.87, 95% CI 0.76-0.97, p = 0.005). Effects remained after controlling for prevalent comorbid neuropathologies. CSF p-tau181/Aβ42 was strongly associated with CERAD ratings of neuritic amyloid plaque scores and Braak staging of NFTs. DISCUSSION: This study supports Lumipulse-measured CSF Aβ42 and p-tau181 and, particularly, the ratio of p-tau181 to Aβ42, for the early detection of AD pathophysiologic processes. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that Lumipulse measures of p-tau181/Aβ42 in the CSF accurately discriminated cognitively normal participants with and without Alzheimer disease neuropathologic change.
引用
- Safransky M, Groh JR, Blennow K, et al. Lumipulse-Measured Cerebrospinal Fluid Biomarkers for the Early Detection of Alzheimer Disease. Neurology. 2024. PMID: 39496102. doi:10.1212/WNL.0000000000209866
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。